Literature DB >> 24436123

Structural analysis of protein-ligand interactions: the binding of endogenous compounds and of synthetic drugs.

Anna M Gallina1, Peer Bork, Domenico Bordo.   

Abstract

The large number of macromolecular structures deposited with the Protein Data Bank (PDB) describing complexes between proteins and either physiological compounds or synthetic drugs made it possible a systematic analysis of the interactions occurring between proteins and their ligands. In this work, the binding pockets of about 4000 PDB protein-ligand complexes were investigated and amino acid and interaction types were analyzed. The residues observed with lowest frequency in protein sequences, Trp, His, Met, Tyr, and Phe, turned out to be the most abundant in binding pockets. Significant differences between drug-like and physiological compounds were found. On average, physiological compounds establish with respect to drugs about twice as many hydrogen bonds with protein atoms, whereas drugs rely more on hydrophobic interactions to establish target selectivity. The large number of PDB structures describing homologous proteins in complex with the same ligand made it possible to analyze the conservation of binding pocket residues among homologous protein structures bound to the same ligand, showing that Gly, Glu, Arg, Asp, His, and Thr are more conserved than other amino acids. Also in the cases in which the same ligand is bound to unrelated proteins, the binding pockets showed significant conservation in the residue types. In this case, the probability of co-occurrence of the same amino acid type in the binding pockets could be up to thirteen times higher than that expected on a random basis. The trends identified in this study may provide an useful guideline in the process of drug design and lead optimization.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drug discovery; lead optimization; protein-ligand interaction; secondary target

Mesh:

Substances:

Year:  2014        PMID: 24436123     DOI: 10.1002/jmr.2332

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  6 in total

1.  Aromatic interactions at the ligand-protein interface: Implications for the development of docking scoring functions.

Authors:  Michal Brylinski
Journal:  Chem Biol Drug Des       Date:  2017-08-31       Impact factor: 2.817

2.  Backbone Brackets and Arginine Tweezers delineate Class I and Class II aminoacyl tRNA synthetases.

Authors:  Florian Kaiser; Sebastian Bittrich; Sebastian Salentin; Christoph Leberecht; V Joachim Haupt; Sarah Krautwurst; Michael Schroeder; Dirk Labudde
Journal:  PLoS Comput Biol       Date:  2018-04-16       Impact factor: 4.475

3.  Binding site identification of G protein-coupled receptors through a 3D Zernike polynomials-based method: application to C. elegans olfactory receptors.

Authors:  Lorenzo Di Rienzo; Luca De Flaviis; Giancarlo Ruocco; Viola Folli; Edoardo Milanetti
Journal:  J Comput Aided Mol Des       Date:  2022-01-01       Impact factor: 3.686

4.  Computational details of molecular structure, spectroscopic properties, topological studies and SARS-Cov-2 enzyme molecular docking simulation of substituted triazolo pyrimidine thione heterocycles.

Authors:  Doaa S El Sayed; El-Sayed M Abdelrehim
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2021-05-26       Impact factor: 4.098

5.  Interaction between a Novel Oligopeptide Fragment of the Human Neurotrophin Receptor TrkB Ectodomain D5 and the C-Terminal Fragment of Tetanus Neurotoxin.

Authors:  Ana Candalija; Thomas Scior; Hans-Richard Rackwitz; Jordan E Ruiz-Castelan; Ygnacio Martinez-Laguna; José Aguilera
Journal:  Molecules       Date:  2021-06-30       Impact factor: 4.411

6.  The Study of Protein-Cyclitol Interactions.

Authors:  Tetiana Dyrda-Terniuk; Mateusz Sugajski; Oleksandra Pryshchepa; Joanna Śliwiak; Magdalena Buszewska-Forajta; Paweł Pomastowski; Bogusław Buszewski
Journal:  Int J Mol Sci       Date:  2022-03-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.